Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.589
-0.035 (-5.58%)
At close: Apr 28, 2026, 4:00 PM EDT
0.589
-0.001 (-0.10%)
After-hours: Apr 28, 2026, 6:43 PM EDT
Galmed Pharmaceuticals Employees
As of December 31, 2025, Galmed Pharmaceuticals had 6 total employees, including 3 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,718,167
Market Cap
3.88M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| AIM ImmunoTech | 21 |
| VivoSim Labs | 14 |
| Azitra | 13 |
| Ensysce Biosciences | 10 |
| Revelation Biosciences | 9 |
| Artelo Biosciences | 7 |
| Alzamend Neuro | 6 |
| 60 Degrees Pharmaceuticals | 3 |
GLMD News
- 14 days ago - Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers - PRNewsWire
- 19 days ago - Galmed Stock Soars On Brain-Penetrating Aramchol Formulation - Benzinga
- 19 days ago - Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol - PRNewsWire
- 4 weeks ago - Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - PRNewsWire
- 3 months ago - Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire
- 5 months ago - Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - PRNewsWire
- 5 months ago - Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - PRNewsWire
- 5 months ago - Galmed Issues CEO Letter to Shareholders - PRNewsWire